chronic hyperkalaemia
Endocrinology · 2019–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| sodium zirconium cyclosilicate Treatment of chronic hyperkalaemia in patients with chronic kidney disease Stage 3-4 who are receiving ≥1 RAASi medicine or are indicated for a RAASi medicine… | Mar 2024 | Recommended with restriction | input received Kidney Health Australia · Zealand Society of Nephrology |
| patiromer Initial and continuing treatment of hyperkalaemia in patients with chronic kidney disease (CKD) Stage 3+ who are receiving one or more renin angiotensin… | Nov 2019 | Not recommended | input received |
Who spoke
Kidney Health Australia · Zealand Society of Nephrology
What the PBS pays
$4M in government benefit over 2024–25, across 10,760 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| patiromer | $4M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.